Global law firm Freshfields has advised Merck KGaA, a leading science and technology company, on the financing of the purchase price for the acquisition of U.S. biopharma company SpringWorks Therapeutics.

SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas). The acquisition strengthens the presence of Merck Healthcare in the United States and expands the reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide.

Freshfields is frequently advising Merck KGaA on financings, M&A transactions and intellectual property matters. The Freshfields team was led by Partner Frank Laudenklos and Principal Associate Dennis Chinnow with support by Principal Associate Laura Korndörfer (all Finance, Frankfurt), Partner Sebastian Röger, Principal Associate Christian Schmidt and Associate Daniel Renner (all Tax, Frankfurt).

The in-house team was led by Tim Nielsen (Head of Capital Markets), Dominic Simm (Director Capital Markets) and Alexander Krüger (Senior Corporate Counsel).